Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Skin (dermatologic) conditions are common in people who are receiving or have received cancer treatment. Sometimes the condition is related to the cancer, and sometimes it is related to cancer treatment. In either case, skin conditions can affect a person's quality of life.
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
In this study, researchers want to find the best dose of RGT-61159 to treat salivary gland cancer. The people in this study have adenoid cystic carcinoma that came back or keeps growing after treatment.
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
Researchers want to find the best dose of CBX-250 to treat leukemia that came back or keeps growing after treatment. The people in this study have one of these diseases:
The purpose of this study is to establish a registry of patients with a rare disease called pediatric-onset opsoclonus myoclonus ataxia syndrome (POOMAS). POOMAS affects the brain, spinal cord, and other nerves. Its exact cause is unknown, though a small number of patients with neuroblastoma may have this condition.
Idecabtagene vicleucel is a form of CAR T immunotherapy for multiple myeloma. People who have this treatment are usually monitored (watched) afterward, with no additional myeloma medications. In this study, researchers want to see if giving iberdomide as maintenance therapy after idecabtagene vicleucel is better than monitoring.
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
